Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PDF Version BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune

Tempest TherapeuticsApr 26 00:00 ET

Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments

TipRanksApr 9 11:25 ET

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

PDF Version BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune

Tempest TherapeuticsApr 9 00:00 ET

Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday's session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Techno

BenzingaApr 5 13:06 ET

Tempest Announces Publication of Positive Data From Phase 1 Trial of TPST-1120 in Patients With Advanced Solid Tumors in Journal of Cancer Research Communications

PDF Version TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive r

Tempest TherapeuticsApr 4 00:00 ET

Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles

TipRanksMar 21 02:01 ET